VHCP Management II
Latest statistics and disclosures from VHCP Management II's latest quarterly 13F-HR filing:
- Top 5 stock holdings are TXG, AXSM, Constellation Pharmceticls I, Biohaven Pharmaceutical Holding, Shockwave Med, and represent 85.94% of VHCP Management II's stock portfolio.
- Added to shares of these 9 stocks: Constellation Pharmceticls I (+$37M), Iveric Bio (+$8.6M), MRSN (+$5.3M), RLMD, Adverum Biotechnologies, Forty Seven, NXTC, Myovant Sciences, ETNB.
- Started 8 new stock positions in Forty Seven, ETNB, Myovant Sciences, MRSN, RLMD, Adverum Biotechnologies, NXTC, Iveric Bio.
- Reduced shares in these 10 stocks: ASND (-$23M), Ra Pharmaceuticals (-$16M), Shockwave Med (-$16M), Biohaven Pharmaceutical Holding (-$14M), AXSM (-$11M), , Kiniksa Pharmaceuticals, La Jolla Pharmaceuticl Com Par, Tricida, PTGX.
- Sold out of its positions in ASND, BCRX, La Jolla Pharmaceuticl Com Par, Prevail Therapeutics Ord, Proteostasis Therapeutics In, Ra Pharmaceuticals, Radius Health, Tricida, Kiniksa Pharmaceuticals.
- VHCP Management II was a net seller of stock by $-41M.
- VHCP Management II has $379M in assets under management (AUM), dropping by 44.56%.
- Central Index Key (CIK): 0001602263
Tip: Access up to 7 years of quarterly data
Positions held by VHCP Management II consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for VHCP Management II
VHCP Management II holds 20 positions in its portfolio as reported in the December 2019 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| 10x Genomics Inc Cl A (TXG) | 35.9 | $136M | 1.8M | 76.25 |
|
|
| Axsome Therapeutics (AXSM) | 21.4 | $81M | -11% | 786k | 103.36 |
|
| Constellation Pharmceticls I | 18.6 | $71M | +106% | 1.5M | 47.11 |
|
| Biohaven Pharmaceutical Holding | 6.6 | $25M | -35% | 463k | 54.44 |
|
| Shockwave Med | 3.3 | $13M | -55% | 289k | 43.92 |
|
| Iveric Bio | 2.3 | $8.6M | NEW | 1.0M | 8.58 |
|
| Kalvista Pharmaceuticals (KALV) | 1.7 | $6.5M | -2% | 366k | 17.81 |
|
| Obseva Sa | 1.6 | $6.0M | -30% | 1.6M | 3.82 |
|
| Mersana Therapeutics (MRSN) | 1.4 | $5.3M | NEW | 923k | 5.73 |
|
| Spero Therapeutics (SPRO) | 1.2 | $4.6M | 474k | 9.62 |
|
|
| Relmada Therapeutics (RLMD) | 1.2 | $4.5M | NEW | 115k | 39.00 |
|
| Adverum Biotechnologies | 1.2 | $4.4M | NEW | 384k | 11.52 |
|
| Marinus Pharmaceuticals | 0.8 | $3.2M | 1.5M | 2.16 |
|
|
| Forty Seven | 0.8 | $3.1M | NEW | 78k | 39.38 |
|
| Milestone Pharmaceuticals (MIST) | 0.6 | $2.4M | 149k | 16.01 |
|
|
| Nextcure (NXTC) | 0.5 | $2.0M | NEW | 36k | 56.33 |
|
| Myovant Sciences | 0.3 | $1.2M | NEW | 77k | 15.51 |
|
| 89bio (ETNB) | 0.3 | $1.1M | NEW | 41k | 26.29 |
|
| Bellerophon Therapeutics | 0.1 | $231k | -84% | 659k | 0.35 |
|
| Protagonist Therapeutics (PTGX) | 0.1 | $227k | -92% | 32k | 7.05 |
|
Past Filings by VHCP Management II
SEC 13F filings are viewable for VHCP Management II going back to 2015
- VHCP Management II 2019 Q4 filed Feb. 13, 2020
- VHCP Management II 2019 Q3 filed Nov. 13, 2019
- VHCP Management II 2019 Q2 filed Aug. 13, 2019
- VHCP Management II 2019 Q1 filed May 14, 2019
- VHCP Management II 2018 Q4 filed Feb. 13, 2019
- VHCP Management II 2018 Q3 filed Nov. 13, 2018
- VHCP Management II 2018 Q2 filed Aug. 13, 2018
- VHCP Management II 2018 Q1 filed May 14, 2018
- VHCP Management II 2017 Q4 filed Feb. 13, 2018
- VHCP Management II 2017 Q3 filed Nov. 13, 2017
- VHCP Management II 2017 Q2 filed Aug. 11, 2017
- VHCP Management II 2017 Q1 filed May 12, 2017
- VHCP Management II 2016 Q4 filed Feb. 13, 2017
- VHCP Management II 2016 Q3 filed Nov. 14, 2016
- VHCP Management II 2016 Q2 filed Aug. 12, 2016
- VHCP Management II 2016 Q1 filed May 13, 2016